文献速递认知障碍与痴呆

初始β-淀粉样蛋白水平与认知正常者后续Flortaucipir PET变化的关系

Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.
PubMed 文献 · JAMA Neurol · 2021-01-01

本研究纳入Mayo Clinic老化研究中65-85岁认知正常者,按基线Aβ PET水平分层,随访约2.7年发现高Aβ组(≥68 CL)在内嗅皮层、下颞叶及AD meta-ROI的flortaucipir累积率显著高于较低Aβ组。ADNI队列重复验证了类似点估计。高Aβ认知正常者适合作为以tau PET为结局的临床试验招募人群。

要点

  • 基线Aβ PET≥68 CL的认知正常老年人,内嗅皮层和下颞叶tau累积最快。
  • 亚阈值和超阈值Aβ组在颞叶区域的tau累积率较最低Aβ组有非显著升高。
  • 以AD meta-ROI年化tau累积下降25%为终点,每组约需216例Aβ≥68 CL的认知正常者。

核心结论

  • 在65-85岁认知正常人群中,基线Aβ PET水平高者(≥68 CL)颞叶区域flortaucipir累积最显著。
  • 招募基线Aβ≥68 CL的认知正常者作为tau PET结局临床试验对象是可行策略。

研究设计与样本

  • 队列研究,纳入Mayo Clinic老化研究中65-85岁认知正常者167例,平均年龄74岁,女性75例(44.9%)。
  • 另纳入ADNI队列认知正常者114例,平均(SD)年龄74.14(5.29)岁,女性64例(56.1%)。
  • 排除缺乏随访PET扫描者101例。
  • 暴露按基线Aβ PET分为低Aβ(≤8 CL)、亚阈值(9-21 CL)、超阈值(22-67 CL)和高Aβ(≥68 CL)。
  • 主要结局为平均2.7年(范围1.1-4.1年)flortaucipir PET在内嗅皮层、下颞叶和外侧顶叶及AD meta-ROI的变化。

主要发现

  • Mayo队列中,高Aβ组内嗅皮层flortaucipir年累积率较超阈值组高0.025(95%CI 0.013-0.037)SUVR单位。
  • 高Aβ组内嗅皮层年累积率较亚阈值组高0.026(95%CI 0.014-0.037)SUVR单位,较低Aβ组高0.034(95%CI 0.02-0.049)SUVR单位。
  • 高Aβ组下颞叶年累积率较超阈值组高0.025(95%CI 0.014-0.035)SUVR单位,较亚阈值组高0.027(95%CI 0.017-0.037)SUVR单位,较低Aβ组高0.035(95%CI 0.022-0.047)SUVR单位。
  • 高Aβ组AD meta-ROI年累积率较超阈值组高0.023(95%CI 0.013-0.032)SUVR单位,较亚阈值组高0.025(95%CI 0.016-0.034)SUVR单位,较低Aβ组高0.032(95%CI 0.021-0.043)SUVR单位(均P < .001)。
  • 亚阈值和超阈值Aβ组颞叶区域flortaucipir累积率较低Aβ组有非显著升高。

关键数值与推荐

  • Aβ PET分组界值:低Aβ≤8 CL,亚阈值9-21 CL,超阈值22-67 CL,高Aβ≥68 CL。
  • AD meta-ROI年化flortaucipir累积率降低25%为终点时,每组需216例基线Aβ≥68 CL的认知正常者(80%把握度)。

临床怎么用

  • 在认知正常老年人中,基线Aβ PET≥68 CL提示后续tau累积较快,可优先作为tau靶向临床试验的招募对象。
  • 以tau PET信号变化为结局的试验,可参考每组约216例Aβ≥68 CL认知正常者的样本量估算。

局限性

  • Mayo队列排除101例缺乏随访PET者,可能引入选择偏倚。
  • ADNI队列方差大于Mayo队列,但下颞叶年化累积点估计相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Tau accumulation in Alzheimer disease (AD) is closely associated with cognitive impairment. Quantitating tau accumulation by positron emission tomography (PET) will be a useful outcome measure for future clinical trials in the AD spectrum. OBJECTIVE: To investigate the association of β-amyloid (Aβ) on PET with subsequent tau accumulation on PET in persons who were cognitively unimpaired (CU) to gain insight into temporal associations between Aβ and tau accumulation and inform clinical trial design. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included individuals aged 65 to 85 years who were CU and had participated in the Mayo Clinic Study of Aging, with serial cognitive assessments, serial magnetic resonance imaging, 11C-Pittsburgh compound B (Aβ) PET scans, and 18F-flortaucipir PET scans, collected from May 2015 to March 2020. Persons were excluded if they lacked follow-up PET scans. A similarly evaluated CU group from the Alzheimer's Disease Neuroimaging Initiative (ADNI) were also studied. These data were collected from September 2015 to March 2020. EXPOSURES: Participants were stratified by index Aβ levels on PET into low Aβ (≤8 centiloid [CL]), subthreshold Aβ (9-21 CL), suprathreshold Aβ (22-67 CL), and high Aβ (≥68 CL). MAIN OUTCOMES AND MEASURES: Changes over a mean of 2.7 (range, 1.1-4.1) years in flortaucipir PET in entorhinal, inferior temporal, and lateral parietal regions of interest and an AD meta-region of interest (ROI). RESULTS: A total of 167 people were included (mean age, 74 [range, 65-85] years; 75 women [44.9%]); 101 individuals were excluded lacking follow-up, and 114 individuals from the ADNI were also studied (mean [SD] age, 74.14 [5.29] years; 64 women [56.1%]). In the Mayo Clinic Study of Aging, longitudinal flortaucipir accumulation rates in the high Aβ group were greater than the suprathreshold, subthreshold, and low Aβ groups in the entorhinal ROI (suprathreshold, 0.025 [95% CI, 0.013-0.037] standardized uptake value ratio [SUVR] units; subthreshold, 0.026 [95% CI, 0.014-0.037] SUVR units; low Aβ, 0.034 [95% CI, 0.02-0.049] SUVR units), inferior temporal ROI (suprathreshold, 0.025 [95% CI, 0.014-0.035] SUVR units; subthreshold, 0.027 [95% CI, 0.017-0.037] SUVR units; low Aβ, 0.035 [95% CI, 0.022-0.047] SUVR units), and the AD meta-ROI (suprathreshold, 0.023 [95% CI, 0.013-0.032] SUVR units; subthreshold, 0.025 [95% CI, 0.016-0.034] SUVR units; low Aβ, 0.032 [95% CI, 0.021-0.043] SUVR units) (all P < .001). Flortaucipir accumulation rates in the subthreshold and suprathreshold Aβ groups in temporal regions were nonsignificantly elevated compared with the low Aβ group. In the ADNI cohort, the variance was larger than in the Mayo Clinic Study of Aging but point estimates for annualized flortaucipir accumulation in the inferior temporal ROI were very similar. An estimated 216 participants who were CU per group with PET Aβ of 68 CL or more would be needed to detect a 25% annualized reduction in flortaucipir accumulation rate in the AD meta-ROI with 80% power. CONCLUSIONS AND RELEVANCE: Substantial flortaucipir accumulation in temporal regions is greatest in persons aged 65 to 85 years who were CU and had high initial Aβ PET levels, compared with those with lower Aβ levels. Recruiting persons who were CU and exhibiting Aβ of 68 CL or more on an index Aβ PET is a feasible strategy to recruit for clinical trials in which a change in tau PET signal is an outcome measure.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Knopman DS, Lundt ES, Therneau TM, et al. Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. JAMA Neurol. 2021. PMID: 33074304. doi:10.1001/jamaneurol.2020.3921

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。